Skip to main content
SpringerLink
Log in

Neuroprotection in Amyotrophic Lateral Sclerosis

  • Chapter
  • First Online:
The Handbook of Neuroprotection

  • 1162 Accesses

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, devastating syndrome that affects both upper and motor neurons. It results in limbs and facial motor weakness, atrophy, spasticity, and death. It is referred to as motor neuron disease in UK and some other European countries, and as Charcot’s disease in France. It is also referred to as Lou Gehrig’s disease in the USA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aebischer P, Cato AC. Playing defense against Lou Gehring’s disease. Sci Am 2007;297:60–7.

    Article  Google Scholar 

  • Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2:696–9.

    Article  PubMed  CAS  Google Scholar 

  • Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:481–8.

    Article  PubMed  CAS  Google Scholar 

  • Cashman N, Tan LY, Krieger C, et al. Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve 2008;37:620–5.

    Article  PubMed  CAS  Google Scholar 

  • Crow JP, Calingasan NY, Chen J, et al. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 2005;58:258–65.

    Article  PubMed  CAS  Google Scholar 

  • Ding H, Schwarz DS, Keene A, et al. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003;2:209–17.

    Article  PubMed  CAS  Google Scholar 

  • Dunckley T, Huentelman MJ, Craig DW, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007;357:775–88.

    Article  PubMed  CAS  Google Scholar 

  • Ferrante Kl, Shefner J, Zhang H, et al. Tolerance of high dose (3000 mg/day) coenzyme Q10 in ALS. Neurology 2005;65:1834–36.

    Article  PubMed  CAS  Google Scholar 

  • Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008;105:2052–7.

    Article  PubMed  CAS  Google Scholar 

  • Gardner SM, Takamiya K, Xia J, et al. Calcium-permeable AMPA receptor plasticity is mediated by subunit-specific interactions with PICK1 and NSF. Neuron 2005;45:903–15.

    Article  PubMed  CAS  Google Scholar 

  • Gordon PH, Moore DH, Gelinas DF, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004;62:1845–7.

    Article  PubMed  CAS  Google Scholar 

  • Gordon Ph, Doorish C, Montes J, et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 2006;66:1117–9.

    Article  PubMed  CAS  Google Scholar 

  • Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nat Genet 2006;38:411–3.

    Article  PubMed  CAS  Google Scholar 

  • Gribkoff VK, Bozik ME. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther 2008;14:215–26.

    Article  PubMed  CAS  Google Scholar 

  • Izumi Y, Kaji R. Clinical trials of ultra-high-dose methylcobalamin in ALS. Brain Nerve 2007;59:1141–7.

    PubMed  CAS  Google Scholar 

  • Jain KK. Scientific and Commercial Aspects of Neuroprotection. Jain PharmaBiotech Publications, Basel, 2010.

    Google Scholar 

  • Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301:839–42.

    Article  PubMed  CAS  Google Scholar 

  • Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402–5.

    Article  PubMed  CAS  Google Scholar 

  • Klein SM, Behrstock S, McHugh J, et al. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 2005;16:509–21.

    Google Scholar 

  • Landers JE, Melki J, Meininger V, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2009;106:9004–9.

    Article  PubMed  CAS  Google Scholar 

  • Lauria G, Campanella A, Filippini G, et al. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler 2009;10:410–5.

    Article  PubMed  CAS  Google Scholar 

  • Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006;66:660–3.

    Article  PubMed  CAS  Google Scholar 

  • Maxwell MM, Pasinelli P, Kazantsev AG, Brown RH. RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells. Proc Natl Acad Sci U S A 2004;101:3178–83.

    Article  PubMed  CAS  Google Scholar 

  • Mazzini L, Fagioli F, Boccaletti R, et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:158–61.

    Article  PubMed  Google Scholar 

  • Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1{beta} accelerates ALS pathogenesis. Proc Natl Acad Sci U S A 2010;107:13046–50.

    Article  PubMed  CAS  Google Scholar 

  • Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:191–206.

    Article  PubMed  CAS  Google Scholar 

  • Neymotin A, Petri S, Calingasan NY, et al. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2009;220:191–7.

    Article  PubMed  CAS  Google Scholar 

  • Patel BP, Hamadeh MJ. Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis. Clin Nutr 2009;28:604–17.

    Article  PubMed  CAS  Google Scholar 

  • Pompl PN, Ho L, Bianchi M, et al. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 2003;17:725–7.

    PubMed  CAS  Google Scholar 

  • Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003;33:455–6.

    Article  PubMed  CAS  Google Scholar 

  • Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11:429–33.

    Article  PubMed  CAS  Google Scholar 

  • Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423–8.

    Article  PubMed  CAS  Google Scholar 

  • Rothstein JD, Patel S, Regan MR, et al. beta-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73–7.

    Article  PubMed  CAS  Google Scholar 

  • Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005;93:1087–98.

    Article  PubMed  CAS  Google Scholar 

  • Siciliano G, Carlesi C, Pasquali L, et al. Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets 2010;9:305–13.

    Article  PubMed  CAS  Google Scholar 

  • Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116:2290–6.

    Article  PubMed  CAS  Google Scholar 

  • Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008;71:1770–5.

    Article  PubMed  CAS  Google Scholar 

  • Sun MM, Bu H, Li B, et al. Neuroprotective potential of phase II enzyme inducer diallyl trisulfide. Neurol Res 2009;31:23–7.

    Article  PubMed  Google Scholar 

  • Traynor BJ, Bruijn L, Conwit R, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006;67:20–7.

    Article  PubMed  CAS  Google Scholar 

  • Urushitani M, Sik A, Sakurai T, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 2006;9:108–18.

    Article  PubMed  CAS  Google Scholar 

  • Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2007;104:2495–500.

    Article  PubMed  CAS  Google Scholar 

  • Wang H, Larriviere KS, Keller KE, et al. R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. Amyotroph Lateral Scler 2008;9:50–8.

    Article  PubMed  Google Scholar 

  • Zhang F, Strom AL, Fukada K, et al. Interaction between Familial Amyotrophic Lateral Sclerosis (ALS)-linked SOD1 Mutants and the Dynein Complex. J Biol Chem 2007;282:16691–9.

    Article  PubMed  CAS  Google Scholar 

  • Zhao Z, Lange DJ, Voustianiouk A, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci 2006;7:29.

    Article  PubMed  Google Scholar 

  • Zhong Z, Ilieva H, Hallagan L, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 2009;119:3437–49.

    PubMed  CAS  Google Scholar 

  • Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74–8.

    Article  PubMed  CAS  Google Scholar 

  • Zoccolella S, Bendotti C, Beghi E, Logroscino G. Homocysteine levels and amyotrophic lateral sclerosis: a possible link. Amyotroph Lateral Scler 2010;11:140–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jain PharmaBiotech, Blaesiring 7, Basel, 4057, Switzerland

    Kewal K. Jain

Authors
  1. Kewal K. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kewal K. Jain .

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Jain, K.K. (2011). Neuroprotection in Amyotrophic Lateral Sclerosis. In: The Handbook of Neuroprotection. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-049-2_10

Download citation

Publish with us

Policies and ethics

Search

Navigation